1Pamer R M J,Ashtor D S,Moncada S.Vascular endothelial cells synthesize nitric oxide from L arginine[J].Nature,1998,333:664- 666.
2Helfrich M H,Evans D E,Grabouski P S,et al.Expression of nitric oxide synthase isoforms in bone and bone cell cultures[J].J Bone Miner Res,1997,12:1108 -1115.
3Armour K E, Armour K J, Gallagher M E,et al.Defective bone formation and anabolic response to exogenous estrogen in mice with targeted disruption of endothelial nitric oxide synthase[J].Endocrinology,2001,142:760- 766.
4Van't Hof R J,Ralston S H. Cytokine induced nitric oxide inhibits bone resorption by inducing apoptosis of osteoclast progenitors and suppressing osteoclast activity[J].J Bone Miner Res,1997,12:1797- 1804.
5Samuels A,Perry M J,Gibson R L,et al.Role of endothelial nitric oxide synthase in estrogen induced osteogenesis[J].Bone,2001,29:24 -29.
6Armour K E, Ralston S H. Estrogen upregulates endothelial constitutive nitric oxide synthase expression in human osteoblast like cells[J].Endocrinology,1998,139:799- 802.
7Armour K E,Van't Hof R J,Grabowski P S,et al.Evidence for a pathogenic role of nitric oxide in inflammation induced osteoporosis[J].J Bone Miner Res,1999,14:2137- 2142.
8Van't Hof R J,Armour K J,Smith L M,et al.Requirement of the inducible nitric oxide synthase pathway for IL 1 induced osteoclastic bone resorption[J].Proc Natl Acad Sci USA,2000,97:7993- 7998.
9Wimalawansa S J,Chapa M T,Yallampalli C,et al.Preventionof corticosteroid induced bone loss with nitric oxide donor nitroglycerin in male rats[J].Bone,1997,21:275 -280.
10Das' U N.Nitric oxide as the mediator of the antiosteoporotic actions of estrogen,statins,and essential fatty acids[J].Exp Biol Med,2002,227:88- 93.
4Trachtman H, Futterweit S, Pine E, et al. Chronic diabetic nephropathy: role of inducible nitric oxide synthase. Pediatr Nephrol, 2002,17:20-29.
5Raij L, Baylis C. Glomerular actions of nitric oxide. Kidney Int, 1995,48:20-32.
6Morris BJ, Markus MA, Glenn CL, et al. Association of a functional inducible nitric oxide synthase promoter variant with complications in type 2 diabetes. J Mol Med, 2002,80:96-104.
7Johannesen J L, Parving HH, Nerup J, et al. CCTTT-repeat polymorphism in the human NOS2-promoter confers low risk of diabetic nephropathy in type 1 diabetic patients. Diabetes Care, 2000,23:560-562.
8Warpeha KM, Charles GI, Patterson CC, et al. Genotyping and functional analysis of a polymorphic (CCTTT)n repeat of NOS2A in diabetic retinopathy. FASEB, 1999,13:1825-1832.
9Cambien F, Poirier O, Nicaud V, et al. Sequence diversity in 36 candidate genes for cardiovascular disorders. Am J Hum Genet, 1999,65:183-191.
10Haynes WG, Hand MF, Dockrell MEC, et al. Physiological role of nitric oxide in regulation of renal function in humans. Am J Physiol, 1997,272: F364-F371.
